← Back to patent-cliff list
Ioflupane (123I)
Tier C — Watch / tradeIoflupane (123I)
Ge Healthcare
Originator
2000
First approval
-
Expiry (public)
No sales data
Peak sales
Radiopharmaceutical
Type
Targets：Not applicable
Brand：DaTSCAN, Striascan
Indications (approved)：Lewy body dementia, Diagnostic agent, Parkinsonism, Alzheimer's disease, Parkinson's disease
Regional status
US
Approved
2011-01-14
EU
Approved
2000-07-27
China
Phase III
2020-06-28
Japan
Approved
2013-09-20
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Ioflupane (123I)?
Approved indications include: Lewy body dementia, Diagnostic agent, Parkinsonism, Alzheimer's disease, Parkinson's disease.
When does the Ioflupane (123I) patent expire?
No public expiry year is available for Ioflupane (123I) yet; this page updates once verified.
How do I get a quote for Ioflupane (123I) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27